Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 38Anemia, Refractory, with Excess of Blasts 31Venous Thromboembolism 24Myelodysplastic Syndromes 21Neoplasms 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia 14Anemia, Aplastic 14Thrombocytopenia 10Lymphoma, Non-Hodgkin 10Lymphoma 10Leukemia, Myelomonocytic, Chronic 10Myeloproliferative Disorders 9Anemia 9Venous Thrombosis 8Primary Myelofibrosis 8Multiple Myeloma 8Hodgkin Disease 8Hematologic Neoplasms 8Cytopenia 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Febrile Neutropenia 7Congenital Bone Marrow Failure Syndromes 7Anemia, Sickle Cell 7Pulmonary Embolism 6Leukemia, Lymphocytic, Chronic, B-Cell 6Leukemia, Biphenotypic, Acute 6Fanconi Anemia 6Bone Marrow Failure Disorders 6Immunologic Deficiency Syndromes 5

Interventions

canakinumab 1X-Rays 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Clonal Cytopenia of Undetermined Significance × Classical hematology × Clear all
NCT05641831 2026-01-02

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
110 enrolled
Classical hematology

Clonal Cytopenia of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡